Advances In™ Treating Interstitial Lung Disease With Progressive Lung Disease Phenotype

Advances In™ Treating Interstitial Lung Disease With Progressive Lung Disease Phenotype is organized by Physicians' Education Resource, LLC (PER).

Release Date: June 30, 2019
Expiration Date: June 30, 2020

Target Audience:
This online educational activity is directed toward immunologists, radiologists, pathologists, primary care physicians, physician assistants, and advanced practice nurses engaged in the care of patients with ILDs.

Accreditation/Credit Designation:
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.

Activity Overview:
Idiopathic pulmonary fibrosis (IPF) is considered the classic presentation of the fibrotic interstitial lung diseases (ILDs). Data suggest that there is a large pool of patients with different clinical ILD presentations and diagnoses who develop a progressive fibrosing phenotype over the course of their disease, resulting in significant challenges in therapy and overall management. With the advent of new therapies in the management of ILDs, it is critical that clinicians be educated on all aspects of the disorder, including earlier identification and differentiation of ILDs, treatment guidelines and clinical management, and IPF risk factors and comorbidities.

Learning Objectives:
Upon successful completion of this educational activity, you should be better prepared to:
• Identify key mechanisms underlying the varied forms of ILDs with progressive lung disease phenotype, clinical presentation, and management
• Assess safety profiles and toxicities of current and emerging therapeutic agents in treatment of ILDs with progressive lung disease phenotype
• Evaluate the efficacy and safety of emerging therapeutic agents targeting treatment of ILD with progressive lung disease phenotype

Additional details will be posted as soon as information is available.